Creative Biolabs is an undisputed leading provider of antibody development and generation services. Now, we provide in vitro diagnostic (IVD) antibody development & immunoassay services targeting various biomarkers of a wide variety of diseases. Especially, we provide customized services targeting tyrosinase-related protein-2 (TYRP2) as a potential biomarker of melanoma.
TYRP2, along with the TYRP1 and enzymes tyrosinase, comprise the tyrosinase family of proteins. These three proteins all contain a transmembrane domain and a histidine-rich, cysteine-rich sequence. They interact to form a 200-700 kDa multimeric complex. This complex is transported from the Golgi apparatus to melanosome vesicles that activate lysosomal-associated membrane proteins (LAMP-1) on the inner surface of the melanosome membrane and thereby protecting the integrity of the melanosome membrane. As a member of the tyrosinase family, TYRP2 is encoded by eight exons located on the 13q31-q32. TYRP2, also known as L-DOPAchrome tautomerase, is the enzyme that has been characterized by the function in the biosynthesis of the pigment and melanin. Compared with the tyrosinase and TRYP1, TRYP2 is the only one that is present in primary and metastatic tumors. With an important role in melanin formation, TYRP2 has great potential for the diagnosis and treatment of melanoma.
Fig.1 Signaling pathways regulating melanogenesis.1
The tyrosinases have been the markers for the melanocyte differentiation and their expression can be associated with the terminally differentiated melanocytes. Moreover, studies have shown that the various expression levels in the human melanoma cells make them be the melanoma-associated antigens for the immunotherapeutic strategies of malignant melanoma treatment. According to a series of experiments, it has been found that the expression of TYRP2 is limited to the cells of neural crest lineage and various tissues of the central nervous system which include the substantianigra, midbrain, forebrain, melanocytes, and melanoma cells. In summary, the TYRP2 can be expressed in melanoma cells specifically while no-detected levels of TYRP2 can be expressed in the non-melanocytic cancer cell lines. In this case, TYRP2 can be served as the biomarker for the diagnosis of melanoma and the potential therapeutic target.
To render more sensitive and precise antibody-based diagnostic tools and assist clinicians in the diagnosis, prognosis, and staging of different diseases and infections, Creative Biolabs provides customized IVD & immunoassay antibody development services to global clients to help generate high-quality antibodies and immunodiagnostic kits. Creative Biolabs has extensive experience in different stages of the immunodiagnostic test development and we offer comprehensive contract development services including but not limited to:
Please feel free to contact us for more information and discuss your project needs.
Reference
For Research Use Only.
